Researchers have discovered that genetic markers linked to brain structure don't predict how well the antipsychotic drug quetiapine will improve cognitive function in people with schizophrenia. This finding challenges a widely held hypothesis about how the medication works and suggests that personalized treatment approaches based on genetics alone may not be as straightforward as scientists hoped.

What Does This Study Tell Us About Schizophrenia Treatment?

Scientists at the Max Planck Institute of Psychiatry examined whether quetiapine, a commonly prescribed antipsychotic, could improve cognitive performance in people with schizophrenia by examining genetic factors. The research team analyzed data from 332 participants across 20 sites in Germany and Austria, tracking cognitive changes over six months in people taking quetiapine compared to those who weren't.

The study focused on a specific theory: that quetiapine might work by helping restore the protective coating around nerve fibers in the brain, a process called remyelination. Researchers hypothesized that people with certain genetic markers suggesting better remyelination capacity would show greater cognitive improvements. However, the results didn't support this idea.

Did Quetiapine Actually Help Cognitive Function?

The picture was mixed. On some cognitive tests, participants showed improvement over time regardless of whether they took quetiapine. For example, both groups improved on the Trail Making Test, a measure of processing speed and mental flexibility. However, quetiapine didn't appear to drive these improvements.

On other tests, quetiapine did show benefits. People taking the medication performed significantly better on backward digit span tests, which measure working memory. They also showed higher scores on the Digit Symbol Substitution Test, a measure of processing speed and attention, and on verbal learning and memory tests at the follow-up visit.

Interestingly, lower doses of quetiapine appeared more effective than higher doses. Participants taking 300 milligrams per day or less showed better working memory performance compared to those on higher doses or those not taking the medication at all.

How to Interpret These Findings for Schizophrenia Care

• Genetic Testing Limitations: The study suggests that genetic markers alone cannot reliably predict which patients will benefit most from quetiapine, meaning doctors cannot yet use genetic testing to personalize antipsychotic selection for individual patients.
• Dose Optimization Matters: Lower doses of quetiapine may be more effective for cognitive improvement than higher doses, suggesting clinicians should carefully consider dosing strategies rather than assuming more medication equals better outcomes.
• Individual Response Variability: Since genetic factors don't explain treatment response, other factors like medication timing, overall health status, and individual brain chemistry likely play important roles in determining who benefits most from antipsychotics.

The research team noted that their findings don't support the hypothesis that genetic estimates of brain remyelination capacity influence how quetiapine affects cognitive performance in schizophrenia. This is important because it suggests the medication may work through different mechanisms than scientists previously believed, or that individual variation in treatment response is too complex to predict using current genetic tools.

The study included 166 participants in the genetic analysis and 106 in the cognitive outcomes analysis, with an average illness duration of about 13 to 15 years. This long-standing illness duration means the participants represented people living with chronic schizophrenia, not newly diagnosed patients.

While these findings may seem disappointing to researchers hoping for genetic biomarkers to guide treatment, they highlight an important reality: mental health treatment remains highly individualized. The fact that quetiapine showed cognitive benefits in some areas, even without genetic predictors, suggests the medication still has value for many patients. However, finding the right dose and monitoring actual cognitive performance over time may be more reliable than genetic testing for determining treatment success.

The study authors acknowledged several limitations, including the lack of randomized treatment assignment and the absence of brain imaging data for some analyses. Future research with more rigorous designs and advanced neuroimaging could provide clearer answers about how antipsychotics affect the brain and which patients are most likely to benefit.